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Abstract 
Heparan sulfate (HS) is a linear, polydisperse sulfated polysaccharide belonging to the 
glycosaminoglycan family. HS proteoglycans are ubiquitously found at the cell surface and 
extracellular matrix in animal species. HS is involved in the interaction with a wide variety of 
proteins and the regulation of many biological activities. In certain pathologic conditions, 
expression and shedding of HS proteoglycans is overregulated, or enzymatic degradation of 
HS in lysosomes is deficient, both leading to excess circulating free HS chains in blood 
plasma. HS has therefore been suggested as a biomarker for various severe disease states. 
The structural heterogeneity makes the quantification of heparan sulfate in complex matrices 
such as human plasma challenging. HS plasma levels are usually quantified by either 
disaccharide analysis or enzyme linked immunosorbent assay (ELISA). Both methods 
require time-consuming multistep-protocols. We describe here the instant detection of 
heparan sulfate in spiked plasma samples by the Heparin Red Kit, a commercial mix-and–
read fluorescence microplate assay. The method enables HS quantification in the low µg/mL 
range without sample pretreatment. Heparin Red appears to be sufficiently sensitive for the 
detection of highly elevated HS levels as reported for mucopolysaccharidosis, graft versus 
host disease after transplantation, dengue infection or septic shock. This study is a 
significant step toward the development of a convenient and fast method for the 
quantification of HS in human plasma, with the potential to simplify the detection and 
advance the acceptance of HS as a biomarker. 
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Introduction 
 
HS structure and biological role 
Heparan sulfate (HS) is a linear, polydisperse sulfated polysaccharide belonging to the 
glycosaminoglycan family. It is built of a major repeating disaccharide unit consisting of 
glucoronic acid and glucosamine (scheme 1) [1, 2]. The glucosamine may be 6-O-sulfated, 
either N-sulfated or N-acetylated, and sporadically 3-O-sulfated, while the glucuronic acid 
may be 2-O-sulfated. Typically, the average degree of sulfation is around one per 
disaccharide. HS proteoglycans are ubiquitously found at the cell surface and extracellular 
matrix in animal species. HS interacts with a large number of proteins and is involved in the 
regulation of many biological activities including cell proliferation, inflammation, 
angiogenesis, viral infectivity and development [3, 4].  
 
Pathologic elevation of HS plasma levels and HS as potential biomarker 
In certain disease states, expression and shedding of HS proteoglycans is overregulated or  
enzymatic degradation of HS in lysosomes is deficient, both leading to excess circulating free 
HS chains in blood plasma that may be partially excreted into urine.  Thus, elevated HS 
levels in plasma, serum or urine have been suggested as a biomarker for a variety of disease 
states, including various types of mucopolysaccharidosis, graft versus host disease (GVHD), 
dengue infection and septic shock. While normal plasma displays a low HS level in the range 
0,1-0,3 µg/mL (as determined by disaccharide analysis, table 1), pathologic HS levels are 
often multifold enhanced (table 2).  
Biomarkers as measurable indicators of normal biological processes, pathogenic processes 
or response to a therapeutic intervention, are becoming increasingly important in diagnosis 
and drug development. Among the large number of potential biomarkers, only few have been 
approved to date by the US FDA. The availability of reliable quantitation techniques is crucial 
for the verification and validation of putative biomarkers.  
The potential of HS as a biomarker is exemplified by graft versus host disease (GVHD), a 
life-threatening complication related to transplantation. After hematopoietic stem cell 
transplantation,  serum HS is highly elevated before the onset of clinical symptoms of GVHD, 
and the HS serum level correlates to the severity of the disease [5]. The early diagnosis and 
treatment (by serum protease inhibitors) of GVHD has been shown to improve survival. 
Therefore, elevated serum or plasma HS levels may serve as an early biomarker of acute 
cellular rejection, and HS level is a relevant parameter for therapy monitoring.  
 
 Quantification 
Method 
HS plasma level  
(µg/mL) 
charge per 
monosaccharide 
Reference 
Carbazole average 0,2 
range 0,1-0,3 (n=6) 
-1.1 [6] 
DS analysis n.d. 
-0,83 a) 
(n=3, male AB serum) 
-1,0  
(n=3, serum from platelet 
poor plasma) 
[7] 
DS analysis range 0,1-0,3 (n=35)  n.d. [8] 
DS analysis range 0,1-0,2 (n=4) -0.55 a) [9] 
DS analysis 
range 0,2-0,3 (n=26) 
(serum, pre-menopausal) 
range 0,1-0,2 (n=25) 
(serum, post-menopausal) 
-0,97 a) 
(pre-menopausal) 
-0,91 
(post-menopausal) 
[10] 
DS analysis average ca. 0,2 (n=16) -0.66 a) [11] 
ELISA average 4,4 
range 0,3-9,8 (n=450) 
n.d. [12] 
ELISA average 5,9 
range 4,8-7,9 (n=10) 
n.d. [13] 
ELISA average ca. 7 
range ca. 5-40 (n=24) 
n.d. [14] 
Table 1. HS concentration and charge in plasma or serum of healthy donors (n: number of donors), 
measured by the carbazole method, disaccharide (DS) analysis, or enzyme linked immunosorbent 
assay (ELISA). All ELISA quantifications used the same commercial kit from the manufacturer 
Seikagaku, Nr. 280564. n.d. means “not detected”. a) Derived from the relative abundance of 
unsulfated, mono-, di- and trisulfated disaccharides as given in the reference. 
 
Methods for HS quantification in plasma or serum 
The structural heterogeneity makes the quantification of heparan sulfate in complex matrices 
such as human plasma challenging. HS level in human plasma or serum is usually quantified 
by either disaccharide analysis (DS analysis) or enzyme linked immunosorbent assay 
(ELISA), see table 1 and table 2 for examples. DS analysis provides not only the HS quantity 
but also valuable information on HS structure. The method is labour-intensive, time-
consuming and requires expensive instrumentation. The tedious multistep-protocols typically 
include extensive plasma sample pretreatment, followed by isolation of HS from plasma by 
chromatographic methods, enzymatic digestion of HS oligomers into disaccharides,  
 Disease  
state 
Quantification 
method 
HS plasma level  
(µg/mL) 
charge per 
monosaccharide 
Reference 
MPS I DS analysis range 0,35-0,65 (n=6)  n.d. [8] 
Indirect lung 
injury DS analysis range 0,4- ca. 10 (n=5) -0.73 
a) [9] 
Rheumatoid 
arthritis DS analysis 
range 0,2-0,4 (n=25) 
(serum, pre-menopausal) 
range 0,3-0,4 (n=25) 
(serum, post-menopausal) 
-1,07 a) 
(pre-menopausal) 
-1,13 
(post-menopausal) 
[10] 
MPS II ELISA average 80 range 4-203 (n=26) n.d. [12] 
Ischemia/early 
reperfusion b) ELISA average 112 (n=5) n.d. [13] 
GVHD 
grade III-IV ELISA 
average 24 (n=11) 
(serum) n.d. [5] 
Dengue c) ELISA average 146 (n=75) range 87-209 n.d. [15] 
Septic shock ELISA average ca. 30 (n=24) range ca. 6-200  
n.d. [14] 
Table 2. HS concentration and charge in plasma or serum of patients (n: number of patients), 
measured by disaccharide (DS) analysis, or enzyme linked immunosorbent assay (ELISA). All ELISA 
quantifications used the same commercial kit from the manufacturer Seikagaku, Nr. 280564. n.d. 
means “not detected”. MPS I / II means “mucopolysaccharidosis type I / II”. GVHD means “graft versus 
host disease”. a) Derived from the relative abundance of unsulfated, mono-, di- and trisulfated 
disaccharides as given in the reference. b) Patients undergoing cardiopulmonary bypass. c) day 5-6 of 
illness.  
 
eventually a modification step such as fluorophore labelling, and finally the identification and 
quantification of disaccharides by LC-MS methods or electrophoresis. Earlier protocols [6] 
have described colorimetric quantification of HS by uronic acid- carbazole reaction, but also 
require a complex procedure for the extraction and purification of HS from plasma.  
The ELISA method is based on two heparan sulfate-specific monoclonal antibodies that 
target N-acetylated and N-sulfated sites of HS. It is easier to perform than disaccharide 
analysis and requires “only” a microplate reader as spectroscopic instrumentation. The 
commonly used ELISA method still requires sample pre-teatment and long incubation times, 
so that overall assay time HS detection in serum sums up to about 40 hours according to the 
protocol of the provider [16]. The ELISA assay commonly detects a much higher (by a factor 
20-40) HS level in human plasma than the disaccharide assays (table 1). All detections listed 
in table 1 used a HS ELISA kit from the same manufacturer. A reasonable explanation is 
 
therefore that the HS calibrant for construction of the standard curve has a lower number of 
epitopes than human plasma HS [14]. 
In one study, the HS content of 18 urine samples (4 samples of normal donors and 14 
samples of MPS and other patients)  was analyzed by both methods: Disaccharide analysis 
and ELISA [12]. The correlation between the two methods was poor, the ELISA/HPLC ratio 
of detected HS ranged between 0.26 and 15.8, i.e. in some samples, ELISA detects a 4 
times lower HS quantity than disaccharide analysis, while in other samples, ELISA detects 
16 times more HS than disaccharide analysis. The discrepancy may be related to the 
structural diversity of HS molecules.  
Assuming that normal HS plasma levels are about 0,2 µg/mL as detected by disaccharide 
analysis (table 1), a tentative “correction” of the ELISA-determined concentrations, based on 
the relative increase of HS over controls or normal levels, yields HS plasma levels in the 
range 1-5 µg/mL for mucopolysaccharidosis, dengue infection, graft versus host disease and 
septic shock (table 2).   
A convenient and fast method for the quantification of heparan sulfate in human plasma or 
serum would simplify the detection of HS and advance its use as a biomarker. We describe 
here as an alternative method for HS detection in human plasma the application of the 
fluorescent probe “Heparin Red”. The latter was initially described as an experimental probe 
for heparin detection [17] and has meanwhile been developed further into commercially 
available assays [18]. Heparin Red is a polyamine modified, red-emissive perylene diimide 
fluorophore (scheme 1, right). It forms a supramolecular aggregate with polysulfated 
polysaccharides, resulting in contact quenching of fluorescence (scheme 2). The strong 
binding of the polycationic probe to polyanionic heparin appears to be controlled by both 
electrostatic and aromatic pi-stacking interactions [19]. In this contribution, we describe for 
the first time application of Heparin Red to the determination of heparan sulfate in human 
plasma. This is to our knowledge the first example for the direct detection of HS plasma 
levels in the low µg/mL range by a mix-and-read optical assay.  
 
 
 
 
                    
Scheme 1. Left: Major glucuronic acid - glucosamine repeating disaccharide unit of heparan sulfate, 
mono-sulfated form. The sulfation pattern is highly variable, possible sites of sulfation are glucuronic 
acid O2 and glucosamine O6 and N (either sulfated or acetylated). The disaccharide moiety may be 
unsulfated, monosulfated, disulfated or (rarely) trisulfated. Right: Structure of the polycationic 
fluorescent probe Heparin Red.   
 
Scheme 2. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of heparan sulfate due to formation of non-fluorescent aggregates.      
 
 
 
Materials and Methods 
 
Instrumentation 
Fluorescence measurements 
Fluorescence was measured with a microplate reader Biotek Synergy Mx (Biotek  
Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 nm,  
spectral band width 13,5-17 nm, gain 90-110 , read height of 8 mm. 
 
Microplates 
For fluorescence measurements 96 well microplates, polystyrene,  Item No 655076, were 
purchased from Greiner Bio-One GmbH, Frickenhausen.  
 
 
Pipettes  
 
Transferpette® 0,5-10µl, Transferpette®-8 20-200µl and Transferpette®-12 20-200µl, 
purchased from Brand GmbH, Wertheim. Rainin Pipettes 100-1000µl, 20-200µl, and 2-20µl 
purchased from Mettler Toledo, OH, USA.  
 
Reagents 
 
Heparin Red® Kit and Heparin Red® Ultra 
The Heparin Red® Kit  was a gift from Redprobes UG, Münster, Germany [18]. Kit 
components: Heparin Red solution, Product No HR001, Lot 01-003, and Enhancer Solution, 
Product No ES001, Lot 004. Heparin Red® Ultra was a gift from Redprobes UG, Münster, 
Germany [18]. Product No HRU001, Lot 003. 
   
Heparan sulfate 
Heparan sulfate from porcine mucosa, highly purified fractions I and III (Cat No GAG-HS I 
and GAG-HS III) were purchased from Iduron Ltd, Cheshire, UK.  
 
Plasma 
Five single-donor citrated plasmas of healthy individuals were provided by the Blood Bank of 
the Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg (IKTZ). The single 
donor plasmas were applied as matrix for the detections shown in figures 4 and 5. The 
heparan sulfate spiked plasmas were stored at -20°C. Pooled normal plasma, applied as 
matrix for the detections shown in figure 3, was prepared by mixing equal volumes of the five 
single donor plasmas.  
 
Other 
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328..   
 
Assays 
 
Heparin Red® Kit 
For determination of heparan sulfate concentrations in plasma or aqueous samples, the 
protocol of the provider for a 96-well microplate assay was followed. Mixtures of Heparin Red 
solution and Enhancer solution (volume ratio 1:90) were freshly prepared. 20 µL of the 
heparan sulfate spiked plasma sample (or heparan sulfate containing aqueous samples) was 
pipetted into a microplate well, followed by 80 µL of the Heparin Red – Enhancer mixture. For 
 
sample numbers > 10, a 12-channel pipette was used for addititon of the Heparin Red – 
Enhancer solution. The microplate was introduced in the fluorescence reader and mixing was 
performed using the plate shaking function of the microplate reader (setting “high”, 3 
minutes). Immediately after mixing, fluorescence was recorded within 1 minute. 
 
Heparin Red® Ultra 
For determination of low heparan sulfate concentrations in aqueous solution, the protocol of 
the provider for a 96-well microplate was modified: 90 µL of the heparan sulfate containing 
sample was pipetted into a microplate well. Then, 90 µL of Heparin Red Ultra solution was 
added to the samples as simultaneously as possible. For sample numbers > 10, a 12-
channel pipette was used for addititon of Heparin Red Ultra solution. The microplate was 
immediately introduced in the fluorescence reader and mixing was performed using the plate 
shaking function of the microplate reader (setting “high”, 1 minute). Immediately after mixing, 
fluorescence was recorded within 1 minute. Detections were performed as duplicates.  
     
Spiked plasma samples 
Plasma samples containing defined mass concentrations of heparin sulfate were prepared by 
adding aqueous solutions (10 vol%) of the corresponding heparan sulfate to plasma and 
vortexing, to achieve a concentration of 100 µg/mL. Heparan sulfate concentrations required 
for the detections were adjusted by further dilution of this 100 µg/mL stock solution with the 
same plasma and vortexing. The spiked plasma samples were stored at -20°C for at least 
one day and up to several months, thawed at room temperature and vortexed before use.  
 
 
  
 
Results and discussion 
 
Detection of heparan sulfate in aqueous samples 
All detections have been performed with spiked samples using commercially available, highly 
purified heparan sulfate fractions (HS I and HS III) from porcine mucosa.  Selected properties 
of HS I and HS III are given in table 3. The fractions differ significantly in molecular weight 
and sulfation degree [20]. The negative charge density per monosaccharide of the HS 
fractions is significantly lower in comparison to heparin (-1,7).   
HS fraction Average mol. weight Average sulfation 
(per disaccharide) 
Average charge density 
(per monosachharide) 
HS I 40 kD 0,75 -0,88 
HS III 9 kD 1,75 -1,38 
Table 3. Selected properties of heparan sulfate fractions HS I and HS III [20].   
The Heparin Red Kit was first applied to the detection of heparan sulfate at different 
concentrations in aqueous samples, using the protocol of the provider for plasma samples. 
Figure 1 shows the decrease of fluorescence signal with increasing heparan sulfate 
concentration. The lower the charge density of the HS, the more HS is needed for 
fluorescence quenching. The ratio of HS III/ HS I monosaccharide charge density (table 1) is 
1,57 what matches well the 1,5-fold higher amount of HS I required to achieve the same 
fluorescence quenching as with HS III (figure 1).  This confirms the suggested formation of 
charge neutral, non-fluorescent aggregates between Heparin Red and sulfated 
polysaccharides in non-competitive matrices [19].  
 
 
 
 
Figure 1. Normalised response curve of the Heparin Red Kit using aqueous heparan sulfate samples 
HS I and HS III in the concentration range 0-10 µg/mL (following protocol of the provider). Manually 
performed microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of 
duplicate determinations; CV’s (averaged over all concentrations) for the linear range 0 to ≈9 µg/mL of 
HS I and HS III 2,7 %.  
 
A higher sensitivity can be achieved when a different commercial assay, Heparin Red Ultra, 
is applied. This assay is preferable for matrices other than plasma or serum [18, 21] and can 
be more readily adapted for higher sensitivity. Using a modified protocol, the detection limit 
for heparan sulfate is about 0,1 µg/mL (figure 2). These results suggest that sensitivities in 
the sub- µg/mL range can be achieved in less complex matrices using the Heparin Red Ultra 
assay.      
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Figure 2. Normalised response curve of Heparin Red Ultra using aqueous heparan sulfate samples 
HS I and HS III in the concentration range 0-1 µg/mL (using an adapted protocol). Manually performed 
microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations; CV (averaged over all concentrations) for the linear range 0 to ≈0,5 µg/mL of HS I: 0,9 
%. CV for the linear range 0 to ≈0,3 µg/mL of HS III: 4,0 %.  
 
Detection of heparan sulfate in pooled normal plasma 
Pooled normal plasma was spiked with HS I or III and the standard protocol for heparin 
detection by the Heparin Red Kit applied (figure 3). The stronger response of Heparin Red to 
HS III than to HS I is confirmed in the plasma matrix. Remarkably, the fluorescence response 
at low HS levels, i.e. about 5 µg/mL HS III and 2 µg/mL HS I, is comparable to that of the 
aqueous matrix (figure 1), indicating only little interference by the plasma matrix. Assuming 
linear response in the range 0-2 µg/mL, the detection limit (3σ of blank, n=6) in pooled 
normal plasma is 1,1 µg/mL for HS I and 0,5 µg/mL for HS III.  At higher HS levels, however, 
the curve flattens, and an increase from 10 to 15 µg/mL HS triggers only a weak further 
fluorescence decrease. We interprete this observation by partial but tight association of 
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Heparin Red with specific plasma components, under formation of a complex in which 
Heparin Red molecules are not aggregated, i.e. still fluorescent. While the uncomplexed 
portion of Heparin Red readily aggregates with HS, there might be an equilibrium between 
the complexed, fluorescent portion of Heparin Red and its nonfluorescent HS aggregate. The 
stronger the aggregates between Heparin Red and the sulfated polysaccharide are, the 
better is the linearity of the response also at higher plasma levels, as observed for 
unfractionated heparin [22] that is expected to form stronger aggregates due to its higher 
charge density of -1,7 per monosaccharide.  
 
 
Figure 3. Normalized response curve of the Heparin Red Kit using heparan sulfate-spiked pool 
plasma samples. HS I and HS III in the concentration range 0-15 µg/mL (following protocol of the 
provider). Manually performed microplate assay. Excitation at 570 nm, fluorescence emission at 605 
nm. Averages of duplicate determinations; CV’s (averaged over all concentrations) of HS I and HS III: 
4,0 %.  
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Detection of heparan sulfate in individual normal plasmas 
To explore the influence of plasma matrix variation on precision of the assay, we have spiked 
plasma samples of 5 healthy donors with HS I and HS III and compared the reponse of the 
Heparin Red Kit (figure 4 and 5). HS Concetrations in the individual plasmas were calculated 
by comparison with the pool plasma calibration curves (figure 3)  and are listed together with  
standard deviations in table 3 and 4.  
 
Figure 4. Response curves of the Heparin Red Kit using heparan sulfate (HS I)-spiked plasma 
samples of 5 healthy donors (BBP_1 – BBP_5), following the protocol of the provider. All fluorescence 
values normalized against the fluorescence of unspiked pool normal plasma (figure 3). Manually 
performed microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of 
duplicate determinations. 
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Spike conc. 
µg/mL HS I 
0,0 2,0 5,0 10,0 15,0 
Mean (µg/mL) -0,4 2,0 5,1 10,9 17,0 
Range (µg/mL) -0,4 - -0,3 1,7-2,3 4,0-5,8 9,2-13,2 14,3-19,3 
SD (µg/mL) 0,04 0,20 0,64 1,33 1,70 
Table 4.  Mean, range and standard deviation (SD) for HS I concentrations as determined by the 
Heparin Red Kit  in 5 spiked plasmas of single healthy donors. Concentrations were derived by 
comparison with the HS I calibration curve for pool plasma (figure 3).   
 
 
Figure 5. Response curves of the Heparin Red Kit using heparan sulfate (HS III)-spiked plasma 
samples of 5 healthy donors (BBP_1 – BBP_5), following the protocol of the provider. All fluorescence 
values normalized against the fluorescence of unspiked pool plasma (figure 3). Manually performed 
microplate assay. Excitation at 570 nm, fluorescence emission at 605 nm. Averages of duplicate 
determinations. 
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Spike conc. 
µg/mL HS III 
0,0 2,0 5,0 10,0 15,0 
Mean (µg/mL) 0,0 1,6 4,9 10,6 15,4 
Range (µg/mL) -0,2 - 0,1 1,4-1,8 4,5-5,4 8,9-12,1 13,7-16,6 
SD (µg/mL) 0,12 0,13 0,30 1,13 1,37 
Table 5.  Mean, range and standard deviation (SD) for HS III concentrations as determined by the 
Heparin Red Kit  in 5 spiked plasmas of single healthy donors. Concentrations were derived by 
comparison with the HS III calibration curve for pool plasma (figure 3).   
Interindividual variation is for both HS types significantly higher than the intraassay variability 
for repeated measurements of the same plasma sample. This indicates a substantial but 
acceptable influence of the plasma matrix on assay results. Interference by endogeneous 
plasma glycosaminoglycans is unlikely: In normal plasma, only chondroitin sulfate is present 
in concentrations that may significantly interfere with the probe. We have already 
demonstrated [23] by chondroitinase treatment of pooled normal plasma that endogeneous 
chondroitin sulfates do not affect Heparin Red fluorescence. Partial binding of either the 
probe Heparin Red (as discussed above) or of HS to specific plasma components may affect 
probe-target interaction and thus contribute to the interindividual variations of fluorescence 
response. Heparin Red has a high affinity to heparin and even competes with excess 
protamine, a strong binder and antagonist of heparin (unpublished results). Nevertheless, 
certain HS-protein complexes are suggested to have nanomolar dissociation constants and 
may impede the interaction with Heparin Red [24].  
The porcine mucosa heparan sulfate fraction HS I has a charge density of -0,88 per 
monosaccharide (table 3) and is a good model for human plasma heparan sulfate for which 
charge densities between -0,55 and -1,1 have been reported (table 1 and 2). Compared with 
unfractionated heparin [22], a significantly higher mass concentration of HS I is required to 
trigger 50% fluorescence quenching. This is interpreted with the higher negative charge 
density of heparin, and the tendency of Heparin Red to form charge neutral aggregates with 
the polyanionic target [19].   
Our experimental data confirm the quantification of HS I in the low µg/mL range by Heparin 
Red, with a detection limit for pooled normal plasma of about 1 µg/mL. Heparin Red has 
therefore the potential to detect highly elevated HS levels in the range 1-5 µg/mL that may 
arise in the course of MPS II, GVHD, Dengue infection or septic shock, by a simple mix-and-
read assay.    
 
 
 
 
Conclusion 
Heparan sulfate is a potential biomarker for a variety disease states, but its quantification in 
complex matrices such as human plasma is challenging. HS levels in plasma are commonly 
determined by either disaccharide analysis or ELISA; both methods require time-consuming 
multistep-protocols. The commercially available Heparin Red Kit enables the detection of HS 
in plasma by a mix-and-read microplate assay within a few minutes. Heparin Red is a 
fluorescent probe that readily forms a non-fluorescent aggregate with HS and enables direct 
detection without plasma sample pretreatment. The assay appears to be sufficiently sensitive 
to detect highly eleveated HS levels in the range 1-5 µg/mL, as reported for 
mucopolysaccharidosis, graft versus host disease after transplantation, dengue infection or 
septic shock. The study was performed with spiked plasma samples, and the ability of the 
assay to detect endogeneous HS in patient samples needs to be confirmed. Our findings 
mark a significant step toward the development of a convenient and fast method for the 
quantification of HS in human plasma, with the potential to simplify the detection and 
advance the acceptance of HS as a biomarker. 
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